New Potent DOT1L Inhibitors forin VivoEvaluation in Mouse.
Stauffer, F., Weiss, A., Scheufler, C., Mobitz, H., Ragot, C., Beyer, K.S., Calkins, K., Guthy, D., Kiffe, M., Van Eerdenbrugh, B., Tiedt, R., Gaul, C.(2019) ACS Med Chem Lett 10: 1655-1660
- PubMed: 31857842 
- DOI: https://doi.org/10.1021/acsmedchemlett.9b00452
- Primary Citation of Related Structures:  
6TE6, 6TEL, 6TEN - PubMed Abstract: 
In MLL-rearranged cancer cells, disruptor of telomeric silencing 1-like protein (DOT1L) is aberrantly recruited to ectopic loci leading to local hypermethylation of H3K79 and consequently misexpression of leukemogenic genes. A structure-guided optimization of a HTS hit led to the discovery of DOT1L inhibitors with subnanomolar potency, allowing testing of the therapeutic principle of DOT1L inhibition in a preclinical mouse tumor xenograft model. Compounds displaying good exposure in mouse and nanomolar inhibition of target gene expression in cells were obtained and tested in vivo.
Organizational Affiliation: 
Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland.